$186 Million is the total value of DAFNA Capital Management LLC's 72 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 31.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | Buy | LOXO ONCOLOGY INC | $24,917,000 | +3.2% | 296,000 | +12.9% | 13.42% | -10.5% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $7,593,000 | +43.4% | 100,691 | +32.5% | 4.09% | +24.4% |
| ATRC | Buy | ATRICURE INC | $7,098,000 | -17.4% | 389,145 | +1.3% | 3.82% | -28.4% |
| AERI | AERIE PHARMACEUTICALS INC | $6,977,000 | +22.9% | 116,770 | 0.0% | 3.76% | +6.6% | |
| ARGX | Buy | ARGENX SEsponsored adr | $6,023,000 | +566.3% | 95,396 | +138.5% | 3.24% | +478.3% |
| BGNE | Sell | BEIGENE LTDsponsored adr | $5,995,000 | -19.3% | 61,349 | -14.6% | 3.23% | -30.0% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $5,859,000 | -6.3% | 1,193,228 | 0.0% | 3.16% | -18.7% | |
| ZGNX | Buy | ZOGENIX INC | $5,373,000 | +192.0% | 134,147 | +155.5% | 2.89% | +153.4% |
| NXTM | NXSTAGE MEDICAL INC | $5,237,000 | -12.2% | 216,119 | 0.0% | 2.82% | -23.9% | |
| ASND | Buy | ASCENDIS PHARMA A Ssponsored adr | $4,993,000 | +90.7% | 124,639 | +72.6% | 2.69% | +65.4% |
| IMMU | Sell | IMMUNOMEDICS INC | $4,913,000 | -23.7% | 304,000 | -34.0% | 2.65% | -33.8% |
| DXCM | Buy | DEXCOM INC | $4,763,000 | +69.3% | 83,000 | +44.3% | 2.56% | +46.8% |
| SAGE | New | SAGE THERAPEUTICS INC | $4,744,000 | – | 28,800 | +100.0% | 2.56% | – |
| VBIV | New | VBI VACCINES INC | $4,261,000 | – | 998,000 | +100.0% | 2.30% | – |
| NBIX | NEUROCRINE BIOSCIENCES INC | $4,229,000 | +26.6% | 54,508 | 0.0% | 2.28% | +9.8% | |
| ALDR | ALDER BIOPHARMACEUTICALS INC | $3,962,000 | -6.5% | 346,013 | 0.0% | 2.13% | -18.9% | |
| RIGL | Buy | RIGEL PHARMACEUTICALS INC | $3,816,000 | +238.9% | 983,478 | +121.8% | 2.06% | +194.0% |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,758,000 | -6.0% | 4,000,000 | 0.0% | 2.02% | -18.5% | ||
| GLPG | Buy | GALAPAGOS NVspon adr | $3,714,000 | +15.5% | 39,609 | +25.3% | 2.00% | +0.2% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $3,323,000 | -5.2% | 361,164 | -17.0% | 1.79% | -17.8% |
| MGNX | MACROGENICS INC | $2,930,000 | +2.8% | 154,200 | 0.0% | 1.58% | -10.8% | |
| SNSS | Sell | SUNESIS PHARMACEUTICALS INC | $2,889,000 | +79.1% | 783,000 | -5.8% | 1.56% | +55.3% |
| IBB | Buy | ISHARES TR NASDQ BIOTECHetf | $2,787,000 | -4.0% | 26,100 | +200.0% | 1.50% | -16.7% |
| ACHN | Buy | ACHILLION PHARMACEUTICALS | $2,731,000 | -15.3% | 948,272 | +32.0% | 1.47% | -26.5% |
| BEAT | Buy | BIOTELEMETRY INC | $2,634,000 | +59.6% | 88,100 | +76.2% | 1.42% | +38.4% |
| VYGR | Buy | VOYAGER THERAPEUTICS INC | $2,606,000 | +8.0% | 157,000 | +33.9% | 1.40% | -6.4% |
| DERM | Buy | DERMIRA INC | $2,392,000 | +17.3% | 86,000 | +13.9% | 1.29% | +1.7% |
| PODD | Sell | INSULET CORP | $2,241,000 | -29.2% | 32,484 | -43.5% | 1.21% | -38.6% |
| PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $2,125,000 | 0.0% | 2,500,000 | 0.0% | 1.14% | -13.3% | ||
| FOMX | Buy | FOAMIX PHARMACEUTICALS LTD | $2,120,000 | +47.6% | 352,741 | +36.4% | 1.14% | +28.0% |
| AKBA | AKEBIA THERAPEUTICS INC | $2,018,000 | -24.4% | 135,738 | 0.0% | 1.09% | -34.4% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $1,891,000 | +9.8% | 349,592 | 0.0% | 1.02% | -4.9% | |
| ARDX | Sell | ARDELYX INC | $1,815,000 | -0.4% | 275,059 | -15.5% | 0.98% | -13.6% |
| KURA | Buy | KURA ONCOLOGY INC | $1,794,000 | +13.3% | 117,281 | +10.8% | 0.97% | -1.7% |
| RDUS | RADIUS HEALTH INC | $1,694,000 | -17.6% | 53,309 | 0.0% | 0.91% | -28.5% | |
| DERMIRA INCnote 3.000% 5/1 | $1,646,000 | +1.4% | 1,500,000 | 0.0% | 0.89% | -12.1% | ||
| AGTC | APPLIED GENETIC TECHNOL CORP | $1,516,000 | -8.8% | 421,000 | 0.0% | 0.82% | -21.0% | |
| New | INSULET CORPnote 1.375% | $1,515,000 | – | 1,500,000 | +100.0% | 0.82% | – | |
| CDTX | Buy | CIDARA THERAPEUTICS INC | $1,472,000 | -12.8% | 216,403 | +3.8% | 0.79% | -24.4% |
| AQXP | Buy | AQUINOX PHARMACEUTICALS INC | $1,399,000 | +23.9% | 118,928 | +49.5% | 0.75% | +7.4% |
| EXAC | EXACTECH INC | $1,361,000 | +50.1% | 27,532 | 0.0% | 0.73% | +30.2% | |
| JNJ | JOHNSON AND JOHNSON | $1,313,000 | +7.4% | 9,400 | 0.0% | 0.71% | -6.9% | |
| IMDZ | New | IMMUNE DESIGN CORP | $1,281,000 | – | 328,500 | +100.0% | 0.69% | – |
| SCPH | New | SCPHARMACEUTICALS INC | $1,186,000 | – | 98,100 | +100.0% | 0.64% | – |
| SCYX | SCYNEXIS INC | $1,176,000 | -3.8% | 506,900 | 0.0% | 0.63% | -16.6% | |
| ARQL | Buy | ARQULE INC | $1,150,000 | +142.1% | 697,192 | +63.1% | 0.62% | +109.8% |
| CARA | CARA THERAPEUTICS INC | $1,148,000 | -10.6% | 93,800 | 0.0% | 0.62% | -22.5% | |
| CMTA | CLEMENTIA PHARMACEUTICALS IN | $1,139,000 | +12.4% | 60,000 | 0.0% | 0.61% | -2.5% | |
| STXS | STEREOTAXIS INC | $1,098,000 | -2.5% | 1,372,862 | 0.0% | 0.59% | -15.5% | |
| XENE | XENON PHARMACEUTICALS INC | $1,067,000 | -4.2% | 377,695 | 0.0% | 0.58% | -16.9% | |
| NERV | MINERVA NEUROSCIENCES INC | $1,035,000 | -20.4% | 171,094 | 0.0% | 0.56% | -31.0% | |
| CGNT | COGENTIX MEDICAL INC | $1,019,000 | +23.1% | 323,482 | 0.0% | 0.55% | +6.8% | |
| PRQR | New | PROQR THERAPEUTICS N V | $744,000 | – | 230,770 | +100.0% | 0.40% | – |
| ADXS | ADVAXIS INC | $701,000 | -32.1% | 247,000 | 0.0% | 0.38% | -41.0% | |
| PTI | New | PROTEOSTASIS THERAPEUTICS IN | $685,000 | – | 117,500 | +100.0% | 0.37% | – |
| LPTX | New | LEAP THERPEUTICS INC | $676,000 | – | 108,330 | +100.0% | 0.36% | – |
| IRONWOOD PHARMACEUTICALS INCdbcv 2.250% 6/1 | $670,000 | -1.8% | 573,000 | 0.0% | 0.36% | -14.7% | ||
| BTX | New | BIOTIME INC | $591,000 | – | 275,000 | +100.0% | 0.32% | – |
| LMNX | LUMINEX CORP DEL | $493,000 | -3.0% | 25,000 | 0.0% | 0.26% | -15.9% | |
| INOTEK PHARMACEUTICALS CORPnote 5.750% 8/0 | $452,000 | -2.0% | 600,000 | 0.0% | 0.24% | -15.0% | ||
| MASI | MASIMO CORPORATION | $424,000 | -2.1% | 5,000 | 0.0% | 0.23% | -15.2% | |
| CASC | Sell | CASCADIAN THERAPEUTICS INC | $395,000 | -17.7% | 106,810 | -9.0% | 0.21% | -28.5% |
| BLUE | Sell | BLUEBIRD BIO INC | $356,000 | -42.4% | 2,000 | -55.6% | 0.19% | -50.0% |
| NTUS | NATUS MEDICAL INC DEL | $302,000 | +2.0% | 7,900 | 0.0% | 0.16% | -11.4% | |
| NEOS | NEOS THERAPEUTICS INC | $281,000 | +11.5% | 27,500 | 0.0% | 0.15% | -3.2% | |
| DEXCOM INCdbcv 0.750% 5/1 | $236,000 | +5.8% | 250,000 | 0.0% | 0.13% | -8.0% | ||
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $218,000 | -42.6% | 9,619 | -51.9% | 0.12% | -50.4% |
| EDGE | EDGE THERAPEUTICS INC | $182,000 | -12.5% | 19,400 | 0.0% | 0.10% | -24.0% | |
| RDHL | New | REDHILL BIOPHARMA LTDsponsored adr | $180,000 | – | 35,000 | +100.0% | 0.10% | – |
| BLCM | BELLICUM PHARMACEUTICALS INC | $168,000 | -27.3% | 20,000 | 0.0% | 0.09% | -37.1% | |
| OBSV | Sell | OBSEVA SA | $139,000 | -80.1% | 14,225 | -83.5% | 0.08% | -82.8% |
| SPRO | New | SPERO THERAPEUTICS INC | $59,000 | – | 5,000 | +100.0% | 0.03% | – |
| GALE | Exit | GALENA BIOPHARMA INC | $0 | – | -46,145 | -100.0% | -0.01% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -44,000 | -100.0% | -0.04% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -5,900 | -100.0% | -0.07% | – |
| SBPH | Exit | SPRING BANK PHARMACEUTICALS | $0 | – | -6,507 | -100.0% | -0.07% | – |
| Exit | INTEC PHARMA LTD JERUSALEM | $0 | – | -14,100 | -100.0% | -0.08% | – | |
| ADMP | Exit | ADAMIS PHARMACEUTICALS CORP | $0 | – | -24,401 | -100.0% | -0.08% | – |
| OPHT | Exit | OPHTHOTECH CORP | $0 | – | -50,000 | -100.0% | -0.09% | – |
| ATNM | Exit | ACTINIUM PHARMACEUTICALS INC | $0 | – | -333,000 | -100.0% | -0.12% | – |
| KDMN | Exit | KADMON HOLDINGS INC | $0 | – | -125,000 | -100.0% | -0.26% | – |
| Exit | NEURODERM LTD | $0 | – | -37,938 | -100.0% | -0.92% | – | |
| QURE | Exit | UNIQURE N V | $0 | – | -175,307 | -100.0% | -1.04% | – |
| Exit | INSULET CORPnote 2.000% 6/1 | $0 | – | -2,250,000 | -100.0% | -1.75% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.